RATIONALE-305: Exploring Adverse Event Profile

Opinion
Video

Panelists discuss how the RATIONALE-305 trial revealed a manageable adverse event profile for tislelizumab plus chemotherapy despite increased rates of neutropenia and anemia compared to placebo plus chemotherapy in advanced gastric cancer patients.

Recent Videos
1 expert is featured in this series.
1 expert is featured in this series.
1 expert is featured in this series.
1 expert is featured in this series.
1 expert is featured in this series.
3 experts are featured in this series.
3 experts are featured in this series.
3 experts are featured in this series.
1 KOL is featured in this series.